You need to repeat it yearly. Multitarget stool DNA test (Cologuard) This combines testing for blood with testing for DNA or gene changes in cells that can get into your poop from polyps ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

But the new, just-launched version of its Cologuard test could spur top-line growth. The improved cancer diagnostic could also help Exact Sciences reach profitability. An updated version of Exact ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Highlights:,Cologuard Plus™ outperforms other noninvasive screening tests in life-years gained and reduces the need for ...

In the initial 10 years since launch, the Cologuard test was used more than 16 million times. Important Information About the Cologuard Test Do not use the Cologuard test if you have had precancer ...

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement ...